Suppr超能文献

新辅助放化疗后手术治疗食管癌的长期疗效:一项针对102例患者的单机构回顾性研究

[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].

作者信息

Ruffier-Loubière A, Janoray G, Chapet S, de Calan L, Dumont P, Dorval É, Orain I, Calais G

机构信息

Clinique d'oncologie-radiothérapie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.

Clinique d'oncologie-radiothérapie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.

出版信息

Cancer Radiother. 2015 Aug;19(5):322-30. doi: 10.1016/j.canrad.2015.04.004. Epub 2015 Jul 26.

Abstract

PURPOSE AND OBJECTIVES

To report survival and morbidity of a large homogeneous cohort of patients with a locally advanced esophageal or cardia carcinoma and put in evidence predictive factors of locoregional control and survival.

PATIENTS AND METHODS

Hundred and two patients were treated at the university hospital of Tours between 1990 and 2010 and received neo-adjuvant chemoradiation therapy with external irradiation (40Gy-44Gy) and two courses of chemotherapy (5-fluoro-uracile and cisplatine). Esophagectomy associated with lymph node dissection was performed about ten weeks after the end of chemoradiation therapy.

RESULTS

The median follow-up was 22.4 months [6-185 months]. The overall survival rates at 2 and 5years were 53% and 27%, respectively. The median overall survival was estimated at 27months. The overall 2-year survival between patients "responders" and patients "non-responders" was 67% vs 26%, respectively (P<0.0001). In case of histological response, there was a benefit in terms of overall survival (P<0.0001), locoregional control (P<0.0036) and disease-free survival (P<0.001). Overall survival at 2years was 64% for ypN0 group vs 32% for ypN1 group (P<0.0001). The median survival was estimated at 37months against 15months in the absence of lymph node involvement (P<0.0001).

CONCLUSION

Our results in terms of survival, tolerance and morbidity and mortality were comparable to those in the literature. Complete histological response of lymph node was associated with an improvement of local control, disease-free survival and overall survival.

摘要

目的和目标

报告一大组局部晚期食管癌或贲门癌患者的生存率和发病率,并找出局部区域控制和生存的预测因素。

患者和方法

1990年至2010年期间,图尔大学医院对102例患者进行了治疗,这些患者接受了新辅助放化疗,包括外照射(40Gy - 44Gy)和两个疗程的化疗(5-氟尿嘧啶和顺铂)。放化疗结束约十周后进行了食管切除术及淋巴结清扫术。

结果

中位随访时间为22.4个月[6 - 185个月]。2年和5年的总生存率分别为53%和27%。中位总生存期估计为27个月。“反应者”和“无反应者”患者的2年总生存率分别为67%和26%(P<0.0001)。在组织学反应方面,总生存期(P<0.0001)、局部区域控制(P<0.0036)和无病生存期(P<0.001)均有获益。ypN0组2年总生存率为64%,ypN1组为32%(P<0.0001)。在无淋巴结受累时,中位生存期估计为37个月,而有淋巴结受累时为15个月(P<0.0001)。

结论

我们在生存、耐受性、发病率和死亡率方面的结果与文献中的结果相当。淋巴结的完全组织学反应与局部控制、无病生存期和总生存期改善相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验